<DOC>
	<DOCNO>NCT00481169</DOCNO>
	<brief_summary>The purpose study determine whether TSE-424 ( bazedoxifene acetate ) , investigational drug , safe effective prevention osteoporosis postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating TSE-424/Placebo/Raloxifene Preventing Osteoporosis Postmenopausal Women</brief_title>
	<detailed_description>Primary objective : To evaluate safety efficacy 3 dos TSE-424 ( bazedoxifene acetate ) , investigational drug , comparison placebo raloxifene prevent osteoporosis postmenopausal woman . Secondary objective : To evaluate effect TSE-424 ( bazedoxifene acetate ) , investigational drug , comparison placebo raloxifene endometrium , metabolic parameter , vasomotor symptom , adverse event , quality life . Samples collect population pharmacokinetic ( PK ) analysis .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy woman 45 year age old least 1 year postmenopausal . Subjects must qualify one follow category ( b ) : ) Greater 1 year less 5 year postmenopausal least one osteoporosis risk factor . b ) Greater 5 year postmenopausal BMD Tscore lumbar spine femoral neck 1 2.5 ( inclusive ) least one osteoporosis risk factor . One ( 1 ) osteoporotic vertebral fracture ( T4L4 ) . Diseases may affect bone metabolism . Past history active nontraumatic venous thromboembolic event , include deep vein thrombosis , pulmonary embolism , retinal vein thrombosis .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>